公开(公告)号：EP4240414A1

公开(公告)日：2023-09-13

申请号：EP21889966.4

申请日：2021-11-03

申请人： The Wistar Institute of Anatomy and Biology

发明人： KULP, Daniel ,  XU, Ziyang ,  WEINER, David

IPC分类号： A61K39/215 ,  A61P31/12 ,  A61P31/14 ,  C07K16/08 ,  C07K16/10

公开(公告)号：EP4114368A1

公开(公告)日：2023-01-11

申请号：EP21708660.2

申请日：2021-03-03

申请人： Active Biotech AB ,  The Wistar Institute Of Anatomy And Biology

发明人： NEFEDOVA, Yuliya ,  TÖRNGREN, Marie ,  ERIKSSON, Helena ,  GABRILOVICH, Dmitry ,  SCHMIDLIN, Fabien

IPC分类号： A61K31/00 ,  A61K31/454 ,  A61K31/47 ,  A61K31/4965 ,  A61P35/00 ,  A61K31/69 ,  C07K16/28

公开(公告)号：EP3601334A1

公开(公告)日：2020-02-05

申请号：EP18778322.0

申请日：2018-03-27

申请人： The Wistar Institute Of Anatomy And Biology ,  Inovio Pharmaceuticals, Inc.

发明人： WISE, Megan ,  WEINER, David

IPC分类号： C07K16/10 ,  C12N15/113 ,  C07K16/46

公开(公告)号：EP3331558A1

公开(公告)日：2018-06-13

申请号：EP16833923.2

申请日：2016-08-05

申请人： The Wistar Institute Of Anatomy And Biology

发明人： ZHANG, Gao ,  LIU, Qin ,  ALTIERI, Dario, Carlo ,  HERLYN, Meenhard

IPC分类号： A61K39/00 ,  A61K39/395 ,  C07K16/00 ,  C07K16/18 ,  C07K16/40

CPC分类号： A61K31/06 ,  A61K31/155 ,  A61K31/245 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/5377 ,  A61K31/713 ,  A61K45/06 ,  A61K2300/00 ,  A61P35/00 ,  C12Q1/6886 ,  C12Q2600/158 ,  G01N33/5743 ,  G01N2800/44 ,  G01N2800/60 ,  G01N2800/7028

摘要： Pharmaceutical compositions for the treatment of cancer are provided. In one embodiment the composition comprises Gamitrinib and a MAPK inhibitor selected from the MAPK inhibitor is selected from RAF265, AZD6244, PLX4720, PD0325901, LGX818, MEK162, vemurafenib, trametinib and dabrafenib. Methods of treating cancer are also provided.

公开(公告)号：EP3298182A1

公开(公告)日：2018-03-28

申请号：EP16797287.6

申请日：2016-05-19

申请人： The Wistar Institute Of Anatomy And Biology

发明人： SHOWE, Louise, C. ,  SHOWE, Michael, K. ,  KOSSENKOV, Andrei, V.

IPC分类号： C40B30/04

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Q2600/178 ,  G06F19/20 ,  G06F19/24 ,  G16H50/70

摘要： A multi-analyte composition for the diagnosis of lung cancer or lung disease comprises a ligand selected from a nucleic acid sequence, polynucleotide or oligonucleotide capable of specifically complexing with, hybridizing to, or identifying an mRNA gene transcript from a mammalian blood sample, and an additional ligand selected from a nucleic acid sequence, polynucleotide or oligonucleotide capable of specifically complexing with, hybridizing to, or identifying an miRNA of a gene from a mammalian blood sample. Each ligand and additional ligand binds to a different gene transcript or miRNA and the gene transcripts and miRNA identified form a characteristic profile of a stage of lung cancer or lung disease. Methods of using this composition for diagnosis and evaluation and methods for developing such compositions are described.

公开(公告)号：EP3068758A1

公开(公告)日：2016-09-21

申请号：EP14861658.4

申请日：2014-11-14

申请人： The Wistar Institute Of Anatomy And Biology

发明人： MESSICK, Troy E. ,  SMITH, Garry R. ,  REITZ, Allen B. ,  LIEBERMAN, Paul M.

IPC分类号： C07C229/56

CPC分类号： C07D207/327 ,  C07C53/18 ,  C07C63/66 ,  C07C65/19 ,  C07C65/28 ,  C07C211/27 ,  C07C217/84 ,  C07C229/56 ,  C07C229/64 ,  C07C233/11 ,  C07C233/64 ,  C07C233/65 ,  C07C235/58 ,  C07C255/54 ,  C07C255/55 ,  C07C311/08 ,  C07C311/16 ,  C07C311/17 ,  C07C317/14 ,  C07C317/44 ,  C07C2601/02 ,  C07D207/08 ,  C07D207/12 ,  C07D207/14 ,  C07D207/16 ,  C07D209/08 ,  C07D211/70 ,  C07D213/55 ,  C07D213/64 ,  C07D213/74 ,  C07D215/14 ,  C07D231/12 ,  C07D235/06 ,  C07D239/26 ,  C07D249/06 ,  C07D277/30 ,  C07D295/155 ,  C07D307/79 ,  C07D333/54 ,  C07D401/04 ,  C07D401/10 ,  C07D403/10 ,  C07D409/10 ,  C07D417/10 ,  C07D471/04 ,  C07D487/04

摘要： The invention provides EBNA1 inhibitors, and pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The compounds and compositions of the invention are further useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. The compounds and compositions of the invention are further useful for the treatment of diseases caused by lytic EBV infection.

摘要翻译： 本发明提供EBNA1抑制剂及其组合物，其可用于治疗由EBNA1活性引起的疾病，例如但不限于癌症，感染性单核细胞增多症，慢性疲劳综合征，多发性硬化症，系统性红斑狼疮和/ 或类风湿性关节炎。 本发明的化合物和组合物还可用于治疗潜伏性EB病毒（EBV）感染引起的疾病。 本发明的化合物和组合物还可用于治疗由溶血性EBV感染引起的疾病。

公开(公告)号：EP2904106A2

公开(公告)日：2015-08-12

申请号：EP13843099.6

申请日：2013-09-30

申请人： The Trustees of the University of Pennsylvania ,  The Wistar Institute Of Anatomy And Biology

发明人： JUNE, Carl, H. ,  PURE, Ellen ,  WANG, Liang-Chuan ,  ALBELDA, Steven ,  SCHOLLER, John

IPC分类号： C12P21/08 ,  C12P19/34 ,  A61K48/00

CPC分类号： C07K16/40 ,  A61K35/17 ,  A61K39/0011 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/18 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/70 ,  C12N2710/10343

摘要： The present invention provides compositions and methods for treating cancer in a human. The invention relates to targeting the stromal cell population in a tumor microenvironment. For example, in one embodiment, the invention provides a composition that is targeted to fibroblast activation protein (FAP). The invention includes a chimeric antigen receptor (CAR) which comprises an anti-FAP domain, a transmembrane domain, and a CD3zeta signaling domain.

公开(公告)号：EP1017421B1

公开(公告)日：2005-05-25

申请号：EP98909027.9

申请日：1998-03-06

申请人： THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY

发明人： HERLYN, Meenhard ,  NESBIT, Mark ,  SATYAMOORTHY, Kapaettu

IPC分类号： A61K48/00 ,  C12N5/16 ,  C12N5/06 ,  C12N15/86 ,  C12N15/11 ,  A61K38/19 ,  A61P17/02

CPC分类号： A61K35/33 ,  A61K35/36 ,  A61K38/1858 ,  A61K38/1866 ,  A61K48/00 ,  A61K49/0008 ,  C12N2799/022 ,  A61K2300/00

摘要： A method for repairing defects and inducing vascularization in mammalian tissue, preferably skin, involves administering to the tissue a recombinant replication defective virus, preferably adenovirus, carrying a selected growth factor gene, preferably VEGF or PDGF, under operative control of regulatory sequences which direct the expression of the growth factor(s). Also provided is a method for infecting a tissue to be transplanted with such recombinant adenoviruses prior to transplantation and, as a composition, an infected culture of human tissue to be transplanted which is infused with a selected growth factor prior to transplantation. Screening methods for the treatment of angiogenic disorders, e.g., hemangiomas and cancers, also employ an animal model on which is engrafted a full thickness human tissue infused with a growth factor.

公开(公告)号：EP1204673A2

公开(公告)日：2002-05-15

申请号：EP00944679.0

申请日：2000-06-14

申请人： THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY

发明人： HALAZONETIS, Thanos ,  Scolnick, Daniel

IPC分类号： C07H21/04 ,  C07K16/00

CPC分类号： C07K14/4702

摘要： An isolated nucleic acid sequence of a mitotic checkpoint gene, chfr, encodes a Chfr protein having a Forkhead-associated domain and a Ring Finger. This protein is required for regulation of the transition of cells from prophase to metaphase during mitosis. The chfr nucleic acid and Chfr polypeptide are useful in diagnosing tumorigenic cells and in screening for drugs which can inhibit the activity of Chfr in a cancer cell, thereby rendering the cell more sensitive to additional anti-tumor therapies.

公开(公告)号：EP1155115A1

公开(公告)日：2001-11-21

申请号：EP00911919.9

申请日：2000-02-23

申请人： THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY

发明人： SANTOLI, Daniela ,  ROVERA, Giovanni ,  CESANO, Alessandra

IPC分类号： C12N5/00 ,  C12N5/02

CPC分类号： C12N5/0636 ,  A61K2035/124 ,  C12N5/0694 ,  C12N2501/23

摘要： TALL-104 cells, and other cytotoxic T cell lines, may be modified to increase the cytotoxicity thereof, to enhance growth properties, and/or to provide a preferred phenotype, e.g., expression of cell surface antigens, function, e.g., change in cytokine production profile, by culturing the cells in an effective amount of IL-15, optionally followed by gamma irradiation to halt proliferation.